Navigation Links
Intarcia Therapeutics Announces Presentation of Final Results From,a Phase 2 Combination Study for the Treatment of Hepatitis C at the,Digestive Disease Week Conference

ive patients in an open-label, multi-center, active-controlled study design. All study patients had genotype-1, the most treatment-resistant type of HCV, and the majority of patients (74%) had high baseline viral load (> 800,000 IU/ml), a well-established negative predictive factor for SVR. Patients received daily injections of omega interferon (25 mcg) for up to 48 weeks. The endpoints for this clinical trial were early viral response (EVR), defined as a 2-log reduction in HCV RNA after 12 weeks of treatment, and SVR, defined as undetectable HCV RNA 24 weeks after completion of 48 weeks of treatment. Response rates are presented in the table below:

    HCV RNA Results           Omega IFN + RBV        Omega IFN Alone

                                    N=67                   N=35

    Early Viral Response (EVR)      84 %                   60 %

    p= 0.014

    Sustained Viral Response

    (SVR) (LOD= 50 IU/ml)           36 %                    6 %

    p= 0.001


With this study, Intarcia also took a step toward testing its hypothesis that approximating continuous drug levels through daily administration of omega interferon may minimize side effects when compared to current interferon therapies. This study demonstrates that omega interferon is well tolerated with only two discontinuations due to adverse events. Results of this Phase 2 study suggest a favorable overall safety profile with no substantial safety issues being identified. Normalization of serum ALT, a marker of reduced liver inflammation, occurred in 100% of patients achieving SVR; and no patients receiving omega interferon with ribavirin experienced relapse during 24 weeks of follow-up after completing 48 weeks of treatment.

Alice Leung, President and Chief Executive Officer of Intarcia stated, "We are excited about the Phase 2 injectable omega interferon combination therapy results presented by Dr. Bacon at the DDW conference. Based on the data so far, we believe that a c
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Intarcia Therapeutics Announces Final Results From a Phase 2 Study of Injectable Omega Interferon plus Ribavirin for the Treatment of Hepatitis C Genotype-1
2. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
3. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
4. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
9. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
10. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
11. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
Post Your Comments:
(Date:10/25/2014)... 2014 In conjunction with DURECT Corporation,s (Nasdaq: ... press release, you are invited to listen to the ... internet on Monday, November 3, 2014 at 4:30 pm ... live audio webcast of the presentation will be available ... clicking "Investor Relations."  If you are unable to participate ...
(Date:10/25/2014)... Oct. 24, 2014  As the building blocks ... company access to diverse skill sets and expertise, ... clock business hours for efficiency. However, effectively managing ... According to recent research, more than ... seeing a project not move forward due to ...
(Date:10/22/2014)... , Oct. 22, 2014  Quest Diagnostics (NYSE: ... information services, today announced that its Board of Directors ... a director, effective December 1, 2014. Including Dr. Leiden, ... is the Chairman, President and CEO of Vertex Pharmaceuticals. ... scientific and commercial experience in the pharmaceutical and biotechnology ...
Breaking Medicine Technology:DURECT Corporation Invites You to Join its Third Quarter 2014 Earnings Conference Call 2Work Around the Clock: Successfully Building & Managing Global Virtual Teams 2Quest Diagnostics Adds Jeffrey M. Leiden, M.D., Ph.D., to Board of Directors 2Quest Diagnostics Adds Jeffrey M. Leiden, M.D., Ph.D., to Board of Directors 3
... May 25, 2011 Cyberonics, Inc. (NASDAQ: CYBX ... will participate in the 2011 Jefferies Global Healthcare Conference on ... Browne, Cyberonics, Senior Vice President, Finance & Chief Financial Officer, ... AM Eastern Time.  A live audio webcast of the presentation ...
... Each month, millions of women suffer from symptoms associated with ... AZO PMS™ -- the only brand available to address ... relief from PMS with a fast acting natural product. ... to a wide range of physical and emotional symptoms that ...
Cached Medicine Technology:New AZO PMS™ Delivers Fast, Natural Relief from Symptoms Associated with Premenstrual Syndrome 2New AZO PMS™ Delivers Fast, Natural Relief from Symptoms Associated with Premenstrual Syndrome 3
(Date:10/25/2014)... Reinberg HealthDay Reporter FRIDAY, ... common cold sores -- herpes simplex -- might increase the ... In fact, being a carrier of certain antibodies to ... researchers found. "The identification of a treatable cause ... breakthrough," said lead researcher Dr. Hugo Lovheim, an associate professor ...
(Date:10/25/2014)... News) -- A large influx of international aid is ... tens of thousands of deaths from the widening Ebola ... Using a specially designed mathematical model, the researchers ... just one densely populated county of hard-hit Liberia -- ... The researchers said that if international aid isn,t ...
(Date:10/25/2014)... News) -- October,s shorter, darker days can trigger a ... to an expert. People affected by seasonal ... lack motivation and even have trouble getting out of ... said Dr. Angelos Halaris, a professor in the department ... Stitch School of Medicine. "Seasonal affective disorder should ...
(Date:10/22/2014)... Austin, TX (PRWEB) October 22, 2014 ... Criminal Minds featuring skin diseases both fictional ... Foundation (CEHMDF), a nonprofit organization committed to advocacy ... wondering if CBS will take the opportunity to impart ... disease. , There are many misconceptions about ...
(Date:10/22/2014)... For Dr. Iris Hunter, a job is more ... of her life’s mission. Her extensive experience in the nonprofit ... FirstLight HomeCare, make it clear that Hunter’s mission is to ... work makes a difference in the lives of others,” Hunter ... much research, I felt ready to start on this journey ...
Breaking Medicine News(10 mins):Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 2Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 3Health News:Experts Predict 'Catastrophic' Ebola Epidemic in West Africa if Aid Delayed 2Health News:Dark Days Here for Folks With Seasonal Depression 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 3Health News:Dr. Iris Hunter to Host Grand Opening of FirstLight HomeCare Tomorrow 2
... dropped most pounds went off diabetes meds and ... News) -- Weight loss plays a major role in ... Duke University Medical Center researchers. , Previous studies ... how food is sent from the stomach to the ...
... Help, a patient safety program launched more than ... of UPMC, has significantly improved communication between caregivers ... a review of the program has found. , ... the nation working with the Josie King Foundation ...
... and development collaboration between leading Australian Institutions, the ... University of Melbourne and Bio-Link Partners Ltd., has ... 2008 New Therapy Grant winners. This prestigious research ... is focussed on development and commercialisation of small ...
... Affirms Industry Dominance, DALLAS, June 18 ... the leader in hosted services for email ... processed a record 20,million prescription transactions through ... accredited center. Over 3,200 active,prescribers across eight ...
... to get up from a ... fall safely, ... AEX: PHI) today announced the launch of the website, http://www.LearnNotToFall.com in ... makers of the popular personal,emergency response system, the site features four sections, ...
... today, released a report ,Australian Dementia Research, that recommends ... $36 million in response to the growing economic and ... Prepared by the Dementia Collaborative Research Centre at the ... over the last six years in dementia research was ...
Cached Medicine News:Health News:Weight Loss After Gastric Bypass Is Key to Easing Diabetes 2Health News:Study finds Children's Hospital patient safety program improves caregiver/family communications 2Health News:Dynamin drug discovery team win prestigious international epilepsy grant 2Health News:Dynamin drug discovery team win prestigious international epilepsy grant 3Health News:Zix Corporation Processes More Than 20 Million Electronic Prescriptions 2Health News:Zix Corporation Processes More Than 20 Million Electronic Prescriptions 3Health News:Philips Web Site Offers Seniors and Caregivers Tips and Techniques for Preventing Falls 2Health News:Philips Web Site Offers Seniors and Caregivers Tips and Techniques for Preventing Falls 3Health News:Invest in a future without dementia 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: